Estefania Oliveros Soles, MD
Advanced Heart Failure and Transplant Cardiology · New York, NYNPI 1386083442
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 58.1% of the total. 2025 is the largest year on record at $6,054, more than ten times the $432 reported in 2019.
Across 68 payments — averaging $161.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$6K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
- Abbott$1K
- United Therapeutics Corporation$528
- AstraZeneca$291
- Cvrx, Inc.$192
- plus $269 from 6 others
Across 15 payments — averaging $7945.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$108K
- Janssen Research & Development, LLC$11K
What the payments were for
- Consulting fees$5,50050%
- Speaking & faculty fees$2,00018%
- Travel & lodging$641%
- Food & beverage$3,13829%
- Education$2722%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 28 | $6,375 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $2,242 |
| Abbott | 7 | $1,077 |
| United Therapeutics Corporation | 5 | $528 |
| AstraZeneca | 9 | $291 |
| Cvrx, Inc. | 1 | $192 |
| Novartis | 4 | $85 |
| Merck | 3 | $48 |
| Amgen | 2 | $43 |
| Scpharmaceuticals Inc. | 1 | $37 |
| Alnylam Pharmaceuticals Inc. | 1 | $35 |
| Medtronic | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$3,121
- OPSUMIT$2,525
- LifeVest$2,000
- CardioMEMS HF System$337
- HeartMate 3 Left Ventricular Dev$322
- REMODULIN$225
- ORENITRAM$224
- Barostim Neo System$192
- CARDIOMEMS$186
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$149
- BRILINTA$125
- TYVASO$111
How this compares
$10,973 in reported general payments places this provider in the 65th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
See all advanced heart failure and transplant cardiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 105 | $2,489,589 |
| AdempasRiociguat | 139 | $1,909,595 |
| OpsumitMacitentan | 101 | $1,288,452 |
| WinrevairSotatercept-Csrk | 13 | $185,786 |
| Sildenafil Citrate | 89 | $79,411 |
| Ambrisentan | 37 | $70,137 |
| EliquisApixaban | 41 | $32,471 |
| Tadalafil | 14 | $29,546 |
| FarxigaDapagliflozin Propanediol | 25 | $25,312 |
| EntrestoSacubitril/Valsartan | 16 | $14,817 |
| Bumetanide | 57 | $3,238 |
| Torsemide | 12 | $461 |
| Furosemide | 54 | $273 |
| Potassium Chloride | 31 | $243 |
| Nifedipine ErNifedipine | 12 | $230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $6,375 | $1,288,452101 claims |
| MerckWinrevair | $48 | $185,78613 claims |
| AstraZenecaFarxiga | $291 | $25,31225 claims |
| NovartisEntresto | $85 | $14,81716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
Other advanced heart failure and transplant cardiology in New York
- Johanna ContrerasNew York$534K
- Sean PinneyNew York$305K
- Mathew MaurerNew York$249K
- Dor LotanNew York$158K
- Nir UrielNew York$125K
- Gabriel SayerNew York$95K
- Parag GoyalNew York$87K
- Alex ReyentovichNew York$49K
- Paolo ColomboNew York$44K
- Melana YuzefpolskayaNew York$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.